Summary

Overview
The global animal rabies vaccine market reached US$ 464.14 million in 2023 and is expected to reach US$ 646.98 million by 2031, growing at a CAGR of 4.2% during the forecast period 2024-2031.
Rabies is one the most deadly zoonotic infections that is spread to people through infected animal bites, and saliva. The most common carriers of this infection are dogs, cats, bats, raccoons, etc. The condition is vaccine-preventible, hence immunization of animals is a necessary and most commonly followed step for eradication.
The rabies vaccine used in veterinary animals is mostly inactivated (killed) which activates the immune cells in the animal to create antibodies against the rabies infection. The other type of rabies vaccine is ORV (oral rabies vaccine) which is a recombinant viral vector-based vaccine, given to wild animals, by incorporating it in food.
Market Dynamics: Drivers
Rising government initiatives to eradicate rabies
Rabies is one of the most common zoonotic infections that spreads to humans through dogs. It has become a burden in many countries, due to the widespread dog population. The government bodies of the endemic nations have been actively taking up rabies eradication programs, with a major action plan to mass vaccinate the dogs. This is a cost-effective strategy and better eliminates the virus spread.
For instance, In 2023, the government of India unveiled the National Action Plan for Dog Mediated Rabies Elimination by 2030 (NAPRE). The initiative aims to achieve zero deaths by 2030 in India caused by dog bite-mediated rabies. One of the core action plans of this initiative is to achieve at least 70 % Anti Rabies vaccination coverage among dogs in a defined geographical area annually for 3 consecutive years.
At the global level, the World Health Organization (WHO), the World Organisation for Animal Health (WOAH), the Food and Agriculture Organization of the United Nations (FAO), and the Global Alliance for Rabies Control (GARC) have forged a strategic collaboration named United Against Rabies (UAR) in the framework of One Health. This collaboration has developed and launched a Global Strategic Plan to end human deaths from dog-mediated rabies by 2030 ‘Zero by 30’.
Additionally, in Africa, numerous dog-mediated rabies control projects and initiatives are being implemented in countries such as in Chad, Eritrea, Kenya, Namibia, Tanzania, and Tunisia.
These government initiatives, focusing on mass dog vaccination strategies are anticipated to create a huge demand for animal rabies vaccine in the forecast period.
Restraints
In some low-income countries, the vaccination drives may not effectively take place due to budget constraints and lack of awareness, limiting the supply of vaccines to these countries. Moreover, raw material supply chain discrepancies may create a hurdle to the production capacities.
Segment Analysis
The global animal rabies vaccine market is segmented based on type, animal type, route of administration, and region.
The inactivated vaccine in the type segment accounted for approximately 45.7% of the global animal rabies vaccine market share.
According to the World Health Organization (WHO) inactivated rabies vaccine is widely available for parenteral vaccination of dogs and has repeatedly been shown to result in a robust immune response in >95% of dogs. Moreover, the majority of the veterinary rabies vaccine manufacturers are focusing on developing this inactivated vaccine due to its non-immunogenic potential and low cost of development.
For instance, below is the list of top animal rabies vaccine manufacturers and the type of vaccine they are manufacturing.
Sr. No Manufacturer Vaccine Vaccine Type
1 Merck & Co., Inc. Nobivac Rabies Inactivated
2 Boehringer Ingelheim International GmbH Rabisin/ Raboral V-RG Inactivated
3 BIO-MED Rabies Vet Inactivated
4 Brilliant Biopharma Rabivac Vet Inactivated
5 Zoetis Services LLC Vanguard Rabies Inactivated
6 Virbac. RABIGEN Mono Inactivated
7 Elanco Rabvac Inactivated
8 Ceva ONRAB Recombinant
Table 1: List of Animal Rabies Vaccine Manufacturers and the Vaccine Type
The above list defines the higher market share of inactivated rabies vaccine. These manufacturers apart from independently supplying, work in collaboration with organizations such as WHO and WOAH (World Organization for Animal Health) to supply these vaccines for animal immunization programs.
For instance, Biogénesis Bagó a Latin American-based animal vaccine manufacturer and supplier, has supplied its inactivated vaccine over 14 years span to 15 countries with more than 138 million doses. Moreover, the company has been working along with WHO to eradicate rabies by 2030.
Geographical Analysis
Asia-Pacific is expected to dominate the market with a 38.6% share in the global animal rabies vaccine market.
Asia-Pacific is the most populous region, not only in terms of human population but also in animal population. According to the World Organization for Animal Health, more than 95% of rabies-related deaths occur in Asia and Africa. Moreover, according to the World Health Organization, Asia and Africa are the most endemic regions for rabies. The transmission rate of rabies from dogs to humans is higher in this region. The figures below define the current rabies endemic regions and publicly available rabies national strategic plans (NSP). South East Asian countries like India, Vietnam, Malaysia, and Indonesia are highly endemic and also have an active NSP, Likewise in the Western Pacific, China is highly endemic and also has an active NSP.



Source: World Health Organization: The Global Health Observatory
These national strategic plans usually revolve around 2 core action plans.
1. To make the rabies vaccine available to the dog-bit person for prophylaxis treatment.
2. To prevent the spread of rabies, by actively immunizing the dogs.
As per WHO’s Zero by 2030 report, the cost of mass dog immunization is far lower than prophylactic treatment of rabies-infected patients in endemic counties. The average mass dog immunization cost per dog is US$4.03 (min: US$ 1.56 - max: US$ 11.33), whereas for human treatment, this cost is nearly US$ 108.
Hence mass dog immunization is an effective control plan in the endemic regions. Asian countries being the most endemic ones combined with the availability of animal rabies vaccine manufacturers, the region is expected to dominate the market.


Market Segmentation
By Type
• Inactivated Vaccine
• Recombinant Vector Vaccine
By Animal Type
• Dogs
• Cats
• Cattle
• Goats & Sheep
• Equines
• Others
By Route of Administration
• Oral
• Parenteral
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o South Korea
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major players in the animal rabies vaccine market include Merck & Co., Inc., Boehringer Ingelheim International GmbH, BIO-MED, Brilliant Biopharma, Zoetis Services LLC, Indian Immunologicals Ltd., Virbac., Elanco, Ceva and Biogénesis Bagóamong others.
Why Purchase the Report?
• To visualize the global animal rabies vaccine market segmentation based on type, animal type, route of administration, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of animal rabies vaccine market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global animal rabies vaccine market report would provide approximately 62 tables, 53 figures, and 187 Pages.
Target Audience 2024
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

ページTOPに戻る

Table of Contents

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Animal Type
3.3. Snippet by Route of Administration
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising incidence of rabies
4.1.1.2. Rising government initiatives to eradicate rabies
4.1.2. Restraints
4.1.2.1. High cost of vaccination programs
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
6.1.2. Market Attractiveness Index, By Type
6.2. Inactivated Vaccine*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Recombinant Vector Vaccine
7. By Animal Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
7.1.2. Market Attractiveness Index, By Animal Type
7.2. Dogs*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cats
7.4. Cattle
7.5. Goats & Sheep
7.6. Equine
7.7. Others
8. By Route of Administration
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Oral*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Parenteral
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. The U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. UK
9.3.6.3. France
9.3.6.4. Italy
9.3.6.5. Spain
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Animal Type
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Merck & Co., Inc.*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. Boehringer Ingelheim International GmbH
11.3. BIO-MED
11.4. Brilliant Biopharma
11.5. Zoetis Services LLC
11.6. Indian Immunologicals Ltd.
11.7. Virbac.
11.8. Elanco
11.9. Ceva
11.10. Biogénesis Bagó
LIST NOT EXHAUSTIVE
12. Appendix
12.1. About Us and Services
12.2. Contact Us